MX419643B - Una composición farmacéutica para usarse en tratar linfoma de células b positivo a cd20 - Google Patents

Una composición farmacéutica para usarse en tratar linfoma de células b positivo a cd20

Info

Publication number
MX419643B
MX419643B MX2020003418A MX2020003418A MX419643B MX 419643 B MX419643 B MX 419643B MX 2020003418 A MX2020003418 A MX 2020003418A MX 2020003418 A MX2020003418 A MX 2020003418A MX 419643 B MX419643 B MX 419643B
Authority
MX
Mexico
Prior art keywords
obituzumab
positive
treatment
cell lymphoma
obinutuzumab
Prior art date
Application number
MX2020003418A
Other languages
English (en)
Spanish (es)
Other versions
MX2020003418A (es
Inventor
Chin-Yu Lin
Mehrdad MOBASHER
Michael Wenger
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64362606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX419643(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2020003418A publication Critical patent/MX2020003418A/es
Publication of MX419643B publication Critical patent/MX419643B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
MX2020003418A 2017-10-19 2018-10-19 Una composición farmacéutica para usarse en tratar linfoma de células b positivo a cd20 MX419643B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762574297P 2017-10-19 2017-10-19
PCT/JP2018/038924 WO2019017499A2 (en) 2017-10-19 2018-10-19 PHARMACEUTICAL COMPOSITION

Publications (2)

Publication Number Publication Date
MX2020003418A MX2020003418A (es) 2020-07-20
MX419643B true MX419643B (es) 2025-01-14

Family

ID=64362606

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020003418A MX419643B (es) 2017-10-19 2018-10-19 Una composición farmacéutica para usarse en tratar linfoma de células b positivo a cd20
MX2024009217A MX2024009217A (es) 2017-10-19 2020-07-13 Tratamiento de linfoma de celulas b positivo a cd20 con obinutuzumab

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024009217A MX2024009217A (es) 2017-10-19 2020-07-13 Tratamiento de linfoma de celulas b positivo a cd20 con obinutuzumab

Country Status (14)

Country Link
US (2) US12129304B2 (enExample)
EP (2) EP3697818B1 (enExample)
JP (2) JP6860652B2 (enExample)
KR (3) KR102906969B1 (enExample)
CN (2) CN111212854A (enExample)
AU (2) AU2018303836B2 (enExample)
BR (1) BR112020007731A2 (enExample)
CA (1) CA3079374A1 (enExample)
ES (1) ES3005784T3 (enExample)
IL (2) IL321935A (enExample)
MX (2) MX419643B (enExample)
PL (1) PL3697818T3 (enExample)
TW (2) TWI805630B (enExample)
WO (1) WO2019017499A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3697818B1 (en) * 2017-10-19 2024-11-27 F. Hoffmann-La Roche AG Treatment of cd20-positive b-cell lymphoma with obinutuzumab
US20240050562A1 (en) * 2019-10-04 2024-02-15 Chugai Seiyaku Kabushiki Kaisha Inhibitor of cell proliferation in obinutuzumab resistant cd20-positive cancer, and medicinal composition, medicine, production, method for inhibiting cell proliferation, therapeutic method, type ii anti-cd20 antibody, compounds, combination of same, enhancer and inducer, each relating thereto
EP4404430A4 (en) 2021-09-17 2025-10-29 Canon Kk POWER TRANSMISSION DEVICE AND POWER RECEPTION DEVICE

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
DK2234600T3 (da) 2007-12-21 2014-09-08 Hoffmann La Roche Antistofformulering
SI3179992T1 (sl) * 2014-08-11 2022-09-30 Acerta Pharma B.V. Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1
US11149091B2 (en) * 2015-12-09 2021-10-19 Cedars-Sinai Medical Center Methods for treating nephrotic syndrome
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
JP6881583B2 (ja) 2017-07-21 2021-06-02 横浜ゴム株式会社 空気入りタイヤ
EP3697818B1 (en) * 2017-10-19 2024-11-27 F. Hoffmann-La Roche AG Treatment of cd20-positive b-cell lymphoma with obinutuzumab

Also Published As

Publication number Publication date
CN120983618A (zh) 2025-11-21
WO2019017499A2 (en) 2019-01-24
JP6860652B2 (ja) 2021-04-21
TWI828593B (zh) 2024-01-01
WO2019017499A3 (en) 2019-02-21
CA3079374A1 (en) 2019-01-24
EP3697818B1 (en) 2024-11-27
BR112020007731A2 (pt) 2020-10-20
PL3697818T3 (pl) 2025-03-24
AU2018303836A1 (en) 2020-05-14
US20250026847A1 (en) 2025-01-23
TW202342099A (zh) 2023-11-01
AU2018303836B2 (en) 2025-04-17
IL321935A (en) 2025-09-01
KR102906969B1 (ko) 2026-01-05
IL273909A (en) 2020-05-31
KR20200067196A (ko) 2020-06-11
KR20260011191A (ko) 2026-01-22
KR20240157135A (ko) 2024-10-31
EP3697818A2 (en) 2020-08-26
US12129304B2 (en) 2024-10-29
IL273909B2 (en) 2025-12-01
JP2019528282A (ja) 2019-10-10
IL273909B1 (en) 2025-08-01
TW201922284A (zh) 2019-06-16
AU2025205481A1 (en) 2025-08-07
ES3005784T3 (en) 2025-03-17
MX2024009217A (es) 2024-11-08
EP4520347A3 (en) 2025-06-04
JP7370357B2 (ja) 2023-10-27
TWI805630B (zh) 2023-06-21
EP4520347A2 (en) 2025-03-12
JP2021152002A (ja) 2021-09-30
MX2020003418A (es) 2020-07-20
KR102766089B1 (ko) 2025-02-13
CN111212854A (zh) 2020-05-29
US20200299398A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
ZA201708692B (en) Antibacterial compounds
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
PH12018500950B1 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
MY193723A (en) Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
MX2015012156A (es) Terapia de induccion de rituximab seguida por terapia de acetato de glatiramer.
EP4289822A3 (en) Benzoimidazol-1,2-yl amides as kv7 channel activators
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX370412B (es) Compuesto antimicotico.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2024009217A (es) Tratamiento de linfoma de celulas b positivo a cd20 con obinutuzumab
JOP20200126B1 (ar) طرق استخدام وتركيبات تحتوي على دولاجلوتيد
PH12017501601A1 (en) Use of isolated fractions of mastic gum for treating optic neuropathy
EP4541423A3 (en) Dosing regimen of avelumab for the treatment of cancer
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
MX2017009313A (es) Formulaciones intravenosas de baclofeno y metodos de tratamiento.
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
MX2015015850A (es) Composiciones de sabor y fragancia que contienen tiopiran-carbaldehido.
MX2017003894A (es) Composiciones de bajo espumado que comprenden n-metil-n-acilglucaminas y el uso de las mismas para el desengrasado de sustratos textiles.
UA91618U (uk) Антимікробний засіб паммосепт плюс
UA97937U (uk) Матеріал для інтерференційних покриттів